Article Data

  • Views 393
  • Dowloads 157

Original Research

Open Access Special Issue

Clinical and pathological examination of 11 cases of ovarian seromucinous tumor at our institute

  • Takao Yamamoto1
  • Kenbun Sone1,*,
  • Ayumi Taguchi1
  • Masako Ikemura2
  • Harunori Honjoh1
  • Akira Nishijima1
  • Satoko Eguchi1
  • Yuichiro Miyamoto1
  • Michihiro Tanikawa1
  • Mayuyo Uchino-Mori1
  • Takayuki Iriyama1
  • Tetsushi Tsuruga1
  • Osamu Wada-Hiraike1
  • Yutaka Osuga1

1Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, 113-8655 Tokyo, Japan

2Department of Pathology, The University of Tokyo Hospital, Bunkyo City, 113-8655 Tokyo, Japan

DOI: 10.22514/ejgo.2022.017 Vol.43,Issue 3,June 2022 pp.127-133

Submitted: 10 April 2022 Accepted: 09 May 2022

Published: 15 June 2022

*Corresponding Author(s): Kenbun Sone E-mail:


Background: Seromucinous tumors, a category of ovarian epithelial tumors, were first described in the 2014 World Health Organization’s (WHO) classification of tumors of the female reproductive organs. However, seromucinous carcinoma was reviewed and removed from the fifth edition of the WHO classification in 2020. We aimed to report our experience with 11 seromucinous ovarian tumors (borderline tumors and carcinomas). Methods: The clinical and pathological features of 11 seromucinous ovarian tumors were examined. In addition, the pathological records of seromucinous carcinoma were re-examined by a pathologist to determine if they could be considered as a new classification. Results: Patient age ranged from 28 to 71 years, with a median age of 45.6 years. The median tumor markers levels were 2.0 ng/mL, 68.0 U/mL, and 36.6 U/mL for CEA, CA 19-9, and CA125, respectively. Pathological findings showed that endometriosis was present in five cases (four seromucinous borderline tumors and one seromucinous carcinoma). Most borderline tumors were diagnosed at an early stage; three were diagnosed with the International Federation of Gynecology and Obstetrics (FIGO) stage IA, three with stage ⅠC1, and one with stage IC2. Two cases of seromucinous carcinoma were diagnosed with FIGO stage IA and two were diagnosed with stage ⅠC2. There were two cases of recurrence; one was a seromucinous borderline tumor and one was a seromucinous carcinoma. All cases were classified as endometrioid carcinoma with mucinous differentiation. Conclusions: Our findings indicated the low reproducibility of seromucinous carcinoma diagnosis. As seromucinous tumors are relatively rare and the literature on them is limited, further studies on this topic are warranted.


seromucinous ovarian tumor; endometriosis; WHO classification

Cite and Share

Takao Yamamoto,Kenbun Sone,Ayumi Taguchi,Masako Ikemura,Harunori Honjoh,Akira Nishijima,Satoko Eguchi,Yuichiro Miyamoto,Michihiro Tanikawa,Mayuyo Uchino-Mori,Takayuki Iriyama,Tetsushi Tsuruga,Osamu Wada-Hiraike,Yutaka Osuga. Clinical and pathological examination of 11 cases of ovarian seromucinous tumor at our institute. European Journal of Gynaecological Oncology. 2022. 43(3);127-133.


[1] Nagamine M, Mikami Y. Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues. Diagnostics. 2020; 10: 77.

[2] Kurman RJ, Shih I. Seromucinous Tumors of the Ovary. what’s in a Name? International Journal of Gynecological Pathology. 2016; 35: 78–81.

[3] Karpathiou G, Chauleur C, Corsini T, Venet M, Habougit C, Honeyman F, et al. Seromucinous ovarian tumor a comparison with the rest of ovarian epithelial tumors. Annals of Diagnostic Pathology. 2017; 27: 28–33.

[4] Idrees R, Din NU, Siddique S, Fatima S, Abdul-Ghafar J, Ahmad Z. Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature. Journal of Ovarian Research. 2021; 14: 47.

[5] Cheung AN, Ellenson LH, Gilks CB, Kim K-R, Kong CS, Lax SF, et al. Female Genital Tumours WHO Classification of Tumours, 5th Edition, Volume 4. International Agency for Research on Cancer (IARC): Lyon. 2020.

[6] Kurman RJ, Shih I. The Dualistic Model of Ovarian Carcinogenesis. The American Journal of Pathology. 2016; 186: 733–747.

[7] Rambau PF, McIntyre JB, Taylor J, Lee S, Ogilvie T, Sienko A, et al. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling do not Support a Category of Seromucinous Carcinoma of the Ovary. American Journal of Surgical Pathology. 2017; 41: 685–695.

[8] Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 who classification: evolving concepts and diagnostic criteria. Virchows Archiv. 2017; 470: 125–142.

[9] Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic Criteria and Behavior of Ovarian Seromucinous (Endocervical-Type Mucinous and Mixed Cell-Type) Tumors. The American Journal of Surgical Pathology. 2002; 26: 1529–1541.

[10] Rodriguez IM, Irving JA, Prat J. Endocervical-like Mucinous Borderline Tumors of the Ovary. The American Journal of Surgical Pathology. 2004; 28: 1311–1318.

[11] Hada T, Miyamoto M, Ishibashi H, Kawauchi H, Soyama H, Matsuura H, et al. Ovarian Seromucinous Borderline Tumors are Histologically Different from Mucinous Borderline Tumors. In Vivo. 2020; 34: 1341–1346.

[12] Dubé V, Roy M, Plante M, Renaud MC, Têtu B. Mucinous Ovarian Tumors of Mullerian-type: an Analysis of 17 Cases Including Borderline Tumors and Intraepithelial, Microinvasive, and Invasive Carcinomas. International Journal of Gynecological Pathology. 2005; 24: 138–146.

[13] Taylor J, McCluggage WG. Ovarian Seromucinous Carcinoma. American Journal of Surgical Pathology. 2015; 39: 983–992.

[14] Matias-Guiu X, Stewart CJR. Endometriosis-associated ovarian neoplasia. Pathology. 2018; 50: 190–204.

[15] Maeda D, Shih I. Pathogenesis and the Role of ARID1a Mutation in Endometriosis-related Ovarian Neoplasms. Advances in Anatomic Pathology. 2013; 20: 45–52.

[16] Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330: 228–231.

[17] Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. The New England Journal of Medicine. 2010; 363: 1532–1543.

[18] Nagai Y, Kishimoto T, Nikaido T, Nishihara K, Matsumoto T, Suzuki C, et al. Squamous Predominance in Mixed-Epithelial Papillary Cystadenomas of Borderline Malignancy of Mullerian Type Arising in Endometriotic Cysts. The American Journal of Surgical Pathology. 2003; 27: 242–247.

[19] Newton CL, Brockbank E, Singh N, Faruqi A. A Case of Stage 4B Seromucinous Ovarian Borderline Tumor with Endometriosis and Review of the Literature. International Journal of Gynecological Pathology. 2017; 36: 195–199.

[20] Mikami Y. Endometriosis-related ovarian neoplasms: pathogenesis and histopathologic features. Diagnostic Histopathology. 2014; 20: 357–363.

[21] Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, et al. The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Journal of Gynecologic Oncology. 2021; 32: e49.

[22] McCluggage WG. Ovarian borderline tumours: a review with comparison of serous and mucinous types. Diagnostic Histopathology. 2014; 20: 333–350.

[23] Rutgers JKL. Mullerian Mucinous/Mixed Epithelial (Seromucinous) Ovarian Tumors. The American Journal of Surgical Pathology. 2016; 21: 206–213.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time